Search

Your search keyword '"Merchea, A."' showing total 802 results
Start Over Author "Merchea, A."
Sorry, I don't understand your search. ×
802 results on '"Merchea, A."'

44. Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study

Author

Bacharach J, Sadri E, Sawhney G, Kopczynski C, and Merchea MM

Subjects
glaucoma, intraocular pressure, prostaglandin analog, rho-kinase inhibitor, Ophthalmology, RE1-994
Abstract

Jason Bacharach,1 Ehsan Sadri,2 Gagan Sawhney,3 Casey Kopczynski,4 Mohinder M Merchea4 1North Bay Eye Associates, Inc, Petaluma, CA, USA; 2Visionary Eye Institute, Newport Beach, CA, USA; 3Georgia Eye Partners, Atlanta, GA, USA; 4Alcon, Inc, Fort Worth, TX, USACorrespondence: Jason Bacharach, North Bay Eye Associates, Inc, 104 Lynch Creek Way, Suite 15, Petaluma, CA, USA, Tel +1(707) 762-3573, Fax +1 (707) 762-6873, Email jbacharach@northbayeye.comPurpose: To determine the effect on intraocular pressure (IOP) of switching to a once-daily netarsudil/latanoprost fixed dose combination (FDC) from various topical treatment regimens including latanoprost monotherapy or latanoprost combined with other IOP-lowering agents for the treatment of open-angle glaucoma or ocular hypertension.Methods: A total of 136 participants enrolled. Eligible participants were aged ≥ 18 years and had a current diagnosis of open-angle glaucoma or ocular hypertension. Additional inclusion criteria were current treatment regimens with latanoprost monotherapy, latanoprost plus 1 additional IOP-lowering agent, or latanoprost plus 2 agents; current IOP-lowering regimen stable for ≥ 30 days prior to baseline visit; treated morning IOP ≥ 20 mmHg at baseline visit; and best corrected visual acuity (BCVA) of 20/100 or better in both eyes. Regardless of their initial regimens, all participants stopped their IOP-lowering medication(s) and were switched directly to netarsudil/latanoprost FDC alone.Results: Participants experienced substantial reductions in IOP. At week 12, the mean percent change from baseline in IOP was − 18.5% (SD 18.96) in the overall study population and was similar in the latanoprost monotherapy group (− 21.2% [SD 17.46]), the latanoprost +1 agent group (− 15.7% [SD 21.91]), and the latanoprost +2 agents group (− 16.9% [SD 17.31]). Less than one-third of participants (31.6%) experienced any ocular adverse event or an ocular adverse event related to treatment (27.2%). The most common ocular adverse event was conjunctival hyperemia (18.4%). Most ocular adverse events were mild, and two severe ocular adverse events of hyperemia (1.5%) were reported; no serious ocular adverse events were reported.Conclusion: In this study, additional IOP lowering was achievable when patients switched to netarsudil/latanoprost FDC after treatment with latanoprost alone or latanoprost with 1 or 2 additional agents. The once-daily administration of netarsudil/latanoprost FDC and reduced treatment burden for those on latanoprost combined with additional agents may prove more manageable for patients.Keywords: glaucoma, intraocular pressure, prostaglandin analog, rho-kinase inhibitor

Published
2025

45. ASO Visual Abstract: Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in Refractory Colorectal and Appendiceal Carcinomatosis—Secondary Analysis of the US PIPAC Collaborative Phase 1 Trial: PIPAC vs ST for PM; Good days & Survival

Author

Waheed, Muhammad Talha, Ruel, Nora, Whelan, Richard L., Fakih, Marwan, Fong, Yuman, Deperalta, Danielle, Merchea, Amit, Sun, Virginia, Krouse, Robert, Dellinger, Thanh H., and Raoof, Mustafa

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results